【摘 要】
：
Background To investigate the effects of atorvastatin on contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS) undergoingselective coronary angiography (CAG) or percutaneou
【机 构】
：
Suzhou Kowloon Hospital Shanghai Jiaotong University Medical School,Jiangsu,China
【出 处】
：
第十二届中国介入心脏病学大会(CIT2014)
论文部分内容阅读
Background To investigate the effects of atorvastatin on contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS) undergoingselective coronary angiography (CAG) or percutaneous coronary intervention (PCI).Methods 132 patients with ACS undergoing selective CAG or PCI were selected from January 2012 to January 2013.All patients were randomly divided into three groups.Group A (41 patients) was given atorvastatin 20 mg/d and 0.9％ sodium chloride with the speed of 1 ml·kg-1·h-1 from 6 hours before procedure to 12 hours after the procedure.Group B (48 patients) was given atorvastatin 80 mg once within 24 hours before the procedure including the agents for group A.Group C (43 patients) was given N-acetylcysteine (NAC) 600 mg bid for 2 days before procedure besides the agents for group A.The venous blood samples were collected from all patients and the serum creatine levels were measured before the procedure and 48-72 hours after the procedure,and eGFR were calculated.Urine samples before and 2 hours,6 hours,24 hours and 48 hours after the procedure were collected from all patients.The neutrophil gelatinase associated lipocalin (NGAL) levels were measured using Enzyme-linked immunospecificassay (ELISA).The incidence of CIN and the changes of Scr,eGFR and urinary NGAL were measured and compared among the three groups in the periprocedural period.
其他文献
Background Long coronary lesions remain a higher risk of unfavorable outcomes after percutaneous coronary intervention and the stent length was recognized an independent factor for DES failure.No larg
Background The choice of revascularization strategy in multivessel coronary disease remains a critical issue in cardiology.No large-scale clinical study of everolimus-eluting Stents (EES) was conducte
Background Scant data exist regarding the impact of diabetes mellitus (DM) status on percutaneous coronary intervention (PCI) for left main (LM) coronary artery disease.We sought to compare the impact
Background TARGET Ⅰ randomized controlled trial (RCT) demonstrated that the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort Medical,Shanghai,China) was
目的 评价富马酸喹硫平600 ～ 750mg/d单药治疗精神分裂症急性期兴奋症状的疗效和安全性.方法 采用前瞻性、单组、开放性的设计,纳入符合ICD-10诊断标准的精神分裂症急性期患者124例,予喹硫平600～750mg/d单药治疗.观察时间为24周,在基线、治疗第1周末、第8周末及第24周末评估患者的治疗效果及安全性.疗效指标为阳性与阴性症状综合症量表(positive and negative
目的 评价富马酸喹硫平单药治疗精神分裂症急性期阴性症状和抑郁症状的疗效.方法 采用前瞻性、单组、开放性的研究设计.纳入符合ICD-10精神分裂症诊断标准的124例精神分裂症急性期住院患者,予富马酸喹硫平600～750mg/d单药治疗,观察时间为24周,在基线、治疗第1周末、第8周末及第24周末评估患者的治疗效果及安全性.疗效指标为阳性与阴性症状综合征量表(PANSS)评分变化、蒙哥马利抑郁量表(M
Background Patients with acute myocardial infarction (AMI) with unprotected left main coronary artery (UPLMCA) as culprit lesion are a high-risk subgroup with a substantial mortality.Primary percutane
Background Second-generation drug eluting stents (DSE) associated with reduced major cardiac events compared to first-generation DES.However,limited data exists as to the clinical outcome of overlappi
Background ST-segment elevation myocardial infarction (STEMI) patients are often accompanied with multivessel disease.The current guideline recommended treating the culprit vessel at the primary percu
Background This article reports the 2-year clinical outcomes of the abtuminal groove-filled biodegradable polymer sirolimus-eluting stent (SES) FIREHAWK (MicroPort Medical,Shanghai,China) compared wit